文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)降低在心血管疾病中的作用。

Role of Lipoprotein(a) Reduction in Cardiovascular Disease.

作者信息

Schuth Uma, Gill Kieran, Telyuk Pyotr, Bawamia Bilal-Reshad, Austin David, Zaman Azfar

机构信息

Faculty of Medicine, St Andrews University, St Andrews KY16 9ST, UK.

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4AX, UK.

出版信息

J Clin Med. 2024 Oct 22;13(21):6311. doi: 10.3390/jcm13216311.

DOI:10.3390/jcm13216311
PMID:39518451
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11546410/
Abstract

Recent studies have shown that lipoprotein(a) (Lp(a)) is an important risk factor for a plethora of different cardiovascular diseases. It has been proven that Lp(a) levels are genetically determined and correlate with risk of cardiovascular disease, independent of lifestyle factors. As of yet, treatment options to reduce Lp(a) levels are limited, but new research into Lp(a) reduction yields promising results. This review delves into Lp(a)'s biochemistry and mechanism of effect, the association between Lp(a) and cardiovascular diseases, and possible therapies to minimise cardiovascular disease.

摘要

最近的研究表明，脂蛋白(a) [Lp(a)] 是多种不同心血管疾病的重要危险因素。已证实Lp(a) 水平由基因决定，且与心血管疾病风险相关，不受生活方式因素影响。截至目前，降低Lp(a) 水平的治疗选择有限，但关于降低Lp(a) 的新研究产生了有前景的结果。这篇综述深入探讨了Lp(a) 的生物化学和作用机制、Lp(a) 与心血管疾病之间的关联，以及将心血管疾病降至最低的可能疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2f/11546410/776f8e8609ab/jcm-13-06311-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2f/11546410/0be7d62a568c/jcm-13-06311-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2f/11546410/776f8e8609ab/jcm-13-06311-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2f/11546410/0be7d62a568c/jcm-13-06311-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2f/11546410/776f8e8609ab/jcm-13-06311-g001.jpg

相似文献

[1]
Role of Lipoprotein(a) Reduction in Cardiovascular Disease.

J Clin Med. 2024-10-22

[2]
Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.

Pharmacotherapy. 2023-10

[3]
[Lipoprotein(a) as a cardiovascular risk factor].

Ned Tijdschr Geneeskd. 2011

[4]
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.

Ann Med. 2020-8

[5]
Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.

Cardiovasc Res. 2022-3-25

[6]
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.

JAMA Cardiol. 2022-7-1

[7]
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.

Arterioscler Thromb Vasc Biol. 2022-1

[8]
Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy.

Biomedicines. 2021-7-19

[9]
Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.

Int J Environ Res Public Health. 2023-9-6

[10]
Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol.

Eur J Prev Cardiol. 2025-1-27

引用本文的文献

[1]
Small Interfering RNA (siRNA) for Cardiorenal Disease: Mechanistic Insights from Preclinical and Clinical Studies.

J Cardiovasc Transl Res. 2025-6-25

本文引用的文献

[1]
Gene Editing for the Treatment of Hypercholesterolemia.

Curr Atheroscler Rep. 2024-5

[2]
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?

Cardiol Ther. 2024-3

[3]
Lipoprotein(a): from Causality to Treatment.

Curr Atheroscler Rep. 2024-3

[4]
Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis.

J Am Coll Cardiol. 2024-1-23

[5]
Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.

Int J Environ Res Public Health. 2023-9-6

[6]
Treatment of Lp(a): Is It the Future or Are We Ready Today?

Curr Atheroscler Rep. 2023-10

[7]
Association between lipoprotein(a) and long-term outcomes after percutaneous coronary intervention for lesions with in-stent restenosis.

J Clin Lipidol. 2023

[8]
[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

Rev Med Liege. 2022-12

[9]
Low lipoprotein(a) concentration is associated with atrial fibrillation: a large retrospective cohort study.

Lipids Health Dis. 2022-11-14

[10]
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

J Clin Lipidol. 2022

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索